Clinical Trial Search

Primary: Functional Connectivity (FC) Changes Between the Left Hippocampus and Left Parietal Cortex — -0.03; 0.13; 0.02; -0.01 Change in z-transformed R-value

Primary: SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F) — 41; 34; 22; 42 Participants — p==0.061

Primary: Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4 in Participants Treated With Ruxolitinib 1.5% Cream Twice a Day (BID)…

Primary: Non-progression Rate at 2 Months — 48.9 percentage of participants

Primary: Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period — -0.27585; -0.46424; -0.48804; -0.48960 loge…

Primary: Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax — 933 Ng/mL

Primary: The Pediatric Asthma Quality of Life Questionnaire (PAQOL) — 5.58; 5.93; 6.49 score on a scale — p=.043

Primary: Rate of Relapse-free Survival at 18 Months — 29; 28; 27; 26 Participants

Primary: Three-year Relapse-free Survival — 61.5; 77.8 percentage of participants

Primary: Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT) — 1; 2 Participants

Primary: Cmax — 3138.41; 2874.52; 0.92; 23884.13 pg/mL

Primary: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period — -0.28; 0.08; 0.41; -1.48 grams per deciliter (g/dL) — p=0.0004

Primary: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period — 0.43; 1.13; 1.62; -0.47 grams per deciliter (g/dL) — p=0.0045

Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants

Primary: Time to Progression (TTP) Following CS1008 in Combination With Sorafenib Compared to Sorafenib Alone in Participants With Advanced Liver Cancer — 2.8; 3.0; 3.9 months